...
首页> 外文期刊>Molecular human reproduction. >Multiplex PCR of polymorphic markers flanking the CFTR gene; a general approach for preimplantation genetic diagnosis of cystic fibrosis.
【24h】

Multiplex PCR of polymorphic markers flanking the CFTR gene; a general approach for preimplantation genetic diagnosis of cystic fibrosis.

机译:CFTR基因两侧的多态性标记的多重PCR;植入前遗传学诊断囊性纤维化的一般方法。

获取原文
获取原文并翻译 | 示例
           

摘要

Cystic fibrosis (CF) is the first monogenic disorder for which single cell preimplantation genetic diagnosis (PGD) has been successfully applied. The spectrum of mutations in CF is extremely heterogeneous, and hence, the development of mutation-specific PGD protocols is impracticable. The current study reports the development and evaluation of a general multiplex marker polymerase chain reaction (PCR) protocol for PGD of CF. Four closely linked highly polymorphic (CA)(n) repeat markers D7S523, D7S486, D7S480 and D7S490, flanking the cystic fibrosis transmembrane regulator (CFTR) gene, were used. In 99% of the single cells tested (100 leukocytes and 50 blastomeres), multiplex PCR results were obtained and the overall allelic drop out (ADO) rate varied from 2 to 5%. After validation for the presence of ADO and additional alleles, 95% of the multiplex PCR results were accepted to construct the marker genotypes. Depending on the genotype of the couple, and taking into account the embryos lost for transfer due to validation criteria (5%), ADO (0-2%) and single recombination (1.1-3%), in general >90% of the embryos could be reliably genotyped by PGD using a single blastomere. The risk of misdiagnosis equals the chance of a double recombination between informative flanking markers and is <0.05%. Therefore, this polymorphic and multi-allelic marker system is a reliable and generally applicable alternative for mutation-directed PGD protocols. Furthermore, it provides a test for the origin of the detected genotype and also gives an indication of the chromosomal ploidy status of the blastomere tested.
机译:囊性纤维化(CF)是第一个成功应用单细胞植入前遗传学诊断(PGD)的单基因疾病。 CF中的突变谱非常不同,因此,开发特定于突变的PGD方案是不可行的。本研究报告了CF的PGD的通用多重标记聚合酶链反应(PCR)方案的开发和评估。使用了四个紧密相连的高度多态性(CA)(n)重复标记D7S523,D7S486,D7S480和D7S490,位于囊性纤维化跨膜调节子(CFTR)基因的侧面。在99%的测试单细胞(100个白细胞和50个卵裂球)中,获得了多重PCR结果,总等位基因剔除率(ADO)从2%更改为5%。验证ADO和其他等位基因的存在后,接受95%的多重PCR结果构建标记基因型。取决于夫妇的基因型,并考虑到由于验证标准(5%),ADO(0-2%)和单一重组(1.1-3%)而失去转移的胚胎,通常> 90%胚胎可以使用单个卵裂球通过PGD可靠地进行基因分型。误诊的风险等于信息丰富的侧翼标记之间发生双重重组的机会,且小于0.05%。因此,该多态和多等位标记系统是突变指导的PGD方案的可靠且普遍适用的替代方案。此外,它提供了对检测到的基因型起源的测试,并且还指示了所测试的卵裂球的染色体倍性状态。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号